Antibodies in late-stage clinical studies

The remarkable increase in the number of antibody therapeutics in late-stage clinical studies that occurred between 2010 and 2021 has been documented in the ‘Antibodies to watch‘ article series, which describes monoclonal antibodies in late-stage clinical studies (i.e., pivotal Phase 2, Phase 2/3 or Phase 3). All articles in the series were published in mAbs, and they are all freely available.

The table below is derived from data included in the latest article in the series, Antibodies to Watch in 2022, published in January 2022. The Antibody Society will update the data every quarter during 2022. Last table update: May 1, 2022.
Data for antibody therapeutic products that have advanced to regulatory review or approval in any country have been excluded from this table, but they are included in a searchable table that can be found here.

Biosimilar antibodies have been excluded from both tables.

Format and Fc modification data were compiled by Drs. Alicia Chenoweth and Silvia Crescioli, King’s College London, who also built the data table below.

Please cite our data as follows: The Antibody Society. Antibody therapeutics in late-stage clinical studies. (date accessed); www.antibodysociety.org/antibodies-in-late-stage-clinical-studies/

INN	Drug Code(s)	Target	Format	Specificity	Backbone	Light Chain	Conjugations/Fusion	Mutations/Modifications	Phase of Clinical Development	Late-stage Clinical Study Indications	Therapeutic Area	Company	Licensee/Partner
Zolbetuximab	iMAB362, Claudiximab, GC-182	Claudin-18.2	Chimeric mAb	Monospecific	IgG1	kappa		None found	Phase 3	Gastric and gastro-esophageal junction adenocarcinoma (NCT03504397, NCT03653507)	Cancer	Astellas
Ziltivekimab	COR-001	IL-6	Human mAb	Monospecific	IgG1	kappa		M252Y S254T T256E. Enhanced half life	Phase 3	Atherosclerotic cardiovascular disease, chronic kidney disease (NCT05021835)	Cardiovascular/hemostasis	AstraZeneca	Novo Nordisk A/S
Zilovertamab	UC-961	ROR1	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3 pending	Mantle cell lymphoma (NCT05431179)	Cancer	Oncternal Therapeutics
Zilovertamab vedotin	MK-2140	ROR1	Humanized mAb	Monospecific	IgG1	kappa	MMAE	None found	Phase 2/3	Diffuse large B-cell lymphoma (NCT05139017)	Cancer	Merck Sharp & Dohme LLC
Zanidatamab	ZW25	HER2, HER2 (biparatopic)	Humanized mAb	Bispecific; scFv-Fc(G1) x Fab-Fc	IgG1	kappa		Hetero HH: T350V-L351Y-F405A-Y407V x T350V-T366L-K392L-T394W	Phase 2 (pivotal) and Phase 3	Biliary tract cancers (NCT04466891); Gastroesophageal adenocarcinoma cancer (NCT05152147; HERIZON-GEA-01)	Cancer	Zymeworks	BeiGene
Zamerovimab + mazorelvimab	SYN023 (mixture of CTB011 + CTB012)	Rabies virus spike glycoprotein	Mixture of 2 humanized mAbs	Two monospecific mAbs	IgG1	kappa		None found	Phase 3	Rabies (NCT04644484)	Infectious disease	Synermore Biologics Co. Ltd.
Zalifrelimab	AGEN1884	CTLA-4	Human mAb	Monospecific	IgG1	kappa		None found	Phase 2 (pivotal)	Cervical cancer (NCT03894215)	Cancer	Agenus Inc.	Betta Pharmaceuticals, Recepta biopharma
Xeligekimab	GR1501	IL-17A	Human mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Plaque psoriasis (ChiCTR2100043223)	Immune-mediated disorders	Genrix (Shanghai) Biopharmaceutical Co. Ltd.
Vunakizumab	SHR-1314	IL-17A	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 2/3 and Phase 3	Ankylosing spondylitis (NCT04840485); Plaque psoriasis (NCT04839016)	Immune-mediated disorders	Atridia Pty Ltd./ Jiangsu Hengrui Medicine Co.
Vilobelimab	BDB-001, IFX-1, CaCP29	Complement 5a	Chimeric mAb	Monospecific	IgG4	kappa		None found	Phase 2/3	Hidradenitis suppurativa; COVID-19 (NCT04449588)	Hemostasis	Inflarx	Staidson (Beijing) Biopharmaceuticals Co., Ltd
Vibostolimab	MK-7684	TIGIT	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3	Non-small cell lung cancer (NCT04738487)	Cancer	Merck Sharp & Dohme Corp.
Upifitamab rilsodotin	XMT-1536	NaPi2b	Humanized mAb	Monospecific	IgG1	kappa	Auristatin F-hydroxypropylamide	None found	Phase 3	Ovarian cancer (NCT05329545)	Cancer	Mersana Therapeutics
Upanovimab	SCTA01, monotherapy and in combination with SCTA01C	SARS-CoV-2	Humanized mAb	Monospecific	IgG1	kappa		L234A/L235A (impair Fc effector functions)	Phase 2/3	COVID-19/SARS-CoV-2 infection (NCT04644185)	Infectious disease	Sinocelltech Ltd.
Tusamitamab ravtansine	SAR408701	CEACAM5	Humanized mAb	Monospecific	IgG1	kappa	DM4	None found	Phase 3	Non-small cell lung cancer (NCT04154956)	Cancer	ImmunoGen	Sanofi
Tozorakimab	MEDI3506	IL-33	Human mAb	Monospecific	IgG1	lambda2		None found	Phase 3	Chronic obstructive pulmonary disease (NCT05166889, NCT05158387 not yet recruiting)	Respiratory	AstraZeneca/MedImmune
Tosatoxumab	AR-301, KBSA301	S. aureus alpha-toxin	Human mAb	Monospecific	IgG1	lambda		None found	Phase 3	Ventilator-associated pneumonia caused by S. aureus (NCT03816956)	Infectious disease	Kenta Biotech Ltd	Aridis Pharmaceuticals, Serum AMR
Tiragolumab	MTIG7192A, RO7092284, RG6058	TIGIT	Human mAb	Monospecific	IgG1	kappa		None found	Phase 3	Non-small cell lung cancer (NCT04294810, NCT04513925); Esophageal cancer (NCT04543617, NCT04540211); Small cell lung carcinoma (NCT04665856; NCT04256421)	Cancer	Genentech
Telisotuzumab vedotin	ABBV-399	cMet	Humanized mAb	Monospecific	IgG1	kappa	MMAE	K222C T223del T225del K447del	Phase 3	Non-small cell lung cancer (NCT04928846)	Cancer	AbbVie
Tebotelimab	MGD013	PD-1 , LAG-3	Humanized DART®; Tandem domain-exchanged Fv	Bispecific	IgG4	kappa		M252Y S254T T256E (half-life extension)	Phase 2/3	Gastric cancer (NCT04082364)	Cancer	Macrogenics	Zai Lab
Tarcocimab	KSI-301	VEGF	Humanized mAb	Monospecific	IgG1	kappa	Antibody-biopolymer conjugate (site-specific conjugation of an 800 kDa branched phosphorylcholine biopolymer)	Fc mutations for inert effector function and site specific conjugation	Phase 3	Diabetic macular edema (NCT04603937, NCT04611152); Macular edema due to retinal vein occlusion (NCT04592419); Wet macular degeneration (NCT04964089, NCT04049266); Non-proliferative diabetic retinopathy (NCT05066230)	Ophthalmic disorders	Kodiak Sciences Inc
Talquetamab	JNJ-64407564	G protein-coupled receptor 5D, CD3	Humanized mAb	Bispecific DuoBody®	IgG4	kappa/lambda		Hetero HH: F405L-R409K x WT; both chains: S228P (hinge-stabilization), F234A-L235A (Fc-silencing)	Phase 2 (pivotal), Phase 3 pending	Multiple myeloma (NCT04634552; (NCT05455320 not yet recruiting))	Cancer	Janssen Research & Development, LLC	Genmab
Tagitanlimab	A167, KL-A167, KLA-167, HBM9167	PD-L1	Humanized mAb	Monospecific	IgG1	kappa		L234A L235A G237A. Reduced effector function	Phase 3 pending	Nasopharyngeal carcinoma (NCT05294172 pending)	Cancer	Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.	Klus Pharma, Harbour BioMed
Tafolecimab	IBI306	PCSK9	Human mAb	Monospecific	IgG2	kappa		None found	Phase 2/3 or 3	Hypercholesterolemia (NCT04709536, NCT04289285); Homozygous familial hypercholesterolemia (NCT04948008, NCT04031742); Heterozygous familial hypercholesterolemia (NCT04179669, NCT04759534)	Cardiovascular / hemostasis	Innovent Biologics (Suzhou) Co. Ltd.
Suvratoxumab	AR-320, MEDI4893	Staphylococcus aureus alpha toxin	Human mAb	Monospecific	IgG1	kappa		M252Y S254T T256E. Enhanced half life	Phase 3 pending	Ventilator Associated Pneumonia caused by Staph aureus (NCT05331885 pending)	Infectious disease	AstraZeneca	Aridis
Suciraslimab	SM03	CD22	Chimeric mAb	Monospecific	IgG1	kappa		None found	Phase 3	Rheumatoid arthritis (NCT04312815)	Immune-mediated disorders	Shenzhen Lonn Ryonn	SinoMab BioScience Limited
Solanezumab	LY-2062430, hM266.2	Amyloid beta, soluble	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 2/3 and Phase 3	Alzheimer's disease (NCT01760005); Cognition disorders (NCT02008357)	Neurological disorders	Eli Lilly and Company
Sibeprenlimab	VIS649	APRIL	Humanized mAb	Monospecific	IgG2	kappa		None found	Phase 3	IgA nephropathy (NCT05248646; NCT05248659)	Immune-mediated disorders	Otsuka Pharmaceutical
Setrusumab	UX143, BPS804, MOR05813	Sclerostin	Human mAb	Monospecific	IgG2	lambda		None found	Phase 2/3	Osteogenesis imperfecta (NCT05125809)	Musculoskeletal disorders	Ultragenyx Pharmaceutical Inc	Mereo BioPharma
Semzuvolimab	UB-421, dB4C7	CD4	Humanized mAb	Monospecific	IgG1	kappa		N297H (Fc-aglycosylated to remove Fc effector function)	Phase 3	HIV infection (NCT04406727, NCT03149211 (not yet recruiting))	Infectious disease	United Biopharma
Sasanlimab	PF-06801591	PD-1	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Non-muscle invasive bladder cancer (NCT04165317)	Cancer	Pfizer
Sabatolimab	MBG453	TIM-3	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Myelodysplastic syndromes and chronic myelomonocytic leukemia (NCT04266301)	Cancer	Novartis
Rulonilimab	F520	PD-1	Chimeric mAb	Monospecific	IgG1	kappa		T250Q N297A M428L; Reduced effector function, increased half-life	Phase 3 pending	Hepatocellular carcinoma (NCT05408221)	Cancer	Shandong New Time Pharmaceutical Co., LTD
Rozanolixizumab	UCB7665	FcRn	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge stabilizing)	Phase 3	Generalized myasthenia gravis (NCT03971422, NCT04124965, NCT04650854); Primary immune thrombocytopenia (NCT04200456, NCT04224688, NCT04596995)	Immune-mediated disorders	UCB Biopharma
Rocatinlimab	KHK4083, AMG451	OX40	Human mAb	Monospecific	IgG1	kappa		None found	Phase 3	Atopic dermatitis (NCT05398445)	Immune-mediated disorders	Kyowa Hakko Kirin	Amgen
Retlirafusp alfa	SHR-1701	PD-L1, TGF-β	Antibody-receptor fusion	Bispecific	IgG4	kappa	Extracellular domain of human TGF-β receptor II	S228P (hinge-stabilization)	Phase 2/3; Phase 3	Colorectal cancer (NCT04856787); Gastric or gastroesophageal junction cancer (NCT04950322); Non-small cell lung cancer (NCT05132413 (not yet recruiting))	Cancer	Jiangsu HengRui Medicine Co., Ltd.	Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Recaticimab	SHR-1209	PCSK9	HumanizedmAb	Monospecific	IgG1	kappa		M252Y, S254T, T256E (half life extension)	Phase 3	Hypercholesterolemia and hyperlipidemia (NCT04849000, NCT04885218); Primary hypercholesterolemia (NCT04844125)	Cardiovascular / hemostasis	Jiangsu HengRui Medicine Co., Ltd.
Quavonlimab	MK-1308, AK107	CTLA-4	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3	Renal cell carcinoma (NCT04736706)	Cancer	Akeso Biopharma	Merck Sharp & Dohme Corp.
Pozelimab	REGN3918	Complement C5	Human mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 2/3 and 3	CD55-deficient protein-losing enteropathy (NCT04209634); Paroxysmal nocturnal hemoglobinuria (NCT04162470); Generalized myasthenia gravis (NCT05070858 (not yet recruiting))	Cardiovascular / hemostasis	Regeneron
Plonmarlimab	TJ003234, TJM2	GM-CSF	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 2/3	COVID-19-related cytokine release syndrome (NCT04341116)	Infectious disease	I-Mab Biopharma Co. Ltd.
Patritumab deruxtecan	U3-1402	HER3	Human mAb	Monospecific	IgG1	kappa	DXd/DX-8951	None found	Phase 3	Epidermal growth factor receptor-mutated non-small cell lung cancer (NCT05338970)	Cancer	Daiichi Sankyo Co., Ltd
Paridiprubart	EB05, NI-0101	Toll-like receptor 4	Humanized mAb	Monospecific	IgG1	kappa		N325S L328F	Phase 2/3	COVID-19-related acute respiratory distress syndrome (NCT04401475)	Respiratory	NovImmune SA	Edesa Biotech
Pamrevlumab	FG-3019	Connective tissue growth factor	Human mAb	Monospecific	IgG1	kappa		None found	Phase 3	Duchenne muscular dystrophy (NCT04632940, NCT04371666); Idiopathic pulmonary fibrosis (NCT04419558, NCT03955146); Pancreatic cancer (NCT03941093, NCT04229004)	Musculoskeletal disorders (secondary areas: Respiratory, Cancer)	FibroGen
Otilimab	GSK3196165, MOR103, MOR-04357	GM-CSF (aka CSF2)	Human mAb	Monospecific	IgG1	lambda		None found	Phase 3	Rheumatoid arthritis (NCT03980483, NCT03970837, NCT04134728, NCT04333147)	Immune-mediated disorders	MorphoSys AG	GlaxoSmithKline
Oregovomab	Mab-B43.13	CA125	Murine mAb	Monospecific	IgG1	kappa		None found	Phase 3	Ovarian cancer (NCT04498117)	Cancer	Quest PharmaTech Inc.	OncoQuest Pharmaceuticals, Inc.
Ongericimab	JS002	PCSK9	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Hyperlipidemia (NCT04781114)	Cardiovascular / hemostasis	Shanghai Junshi Bioscience Co Ltd
Onfekafusp alfa	L19TNF, L19(scFv)2-TNF	Fibronectin extra-domain B	Human mAb	Monospecific	scFv fused with TNF		scFv fused with TNF	None found	Phase 3	Soft tissue sarcoma (NCT04650984); melanoma (NCT03567889, in combination with L19IL2)	Cancer	Philogen S.p.A.
Oleclumab	MEDI9447	CD73	Human mAb	Monospecific	IgG1	lambda1		L234F L235E P331S. Reduced effector function	Phase 3	Non-small cell lung cancer (NCT05221840)	Cancer	AstraZeneca
Odronextamab	REGN1979	CD20, CD3	Human mAb	Bispecific	IgG4; Hetero H, cL	kappa		Hetero HH: WT x H435R-Y436F (limits binding to Protein A, purification); HL-pairing: cL ; both chains: E233P, F234V, L235A, G236del (Fc-silencing), S228P (hinge-stabilization)	Phase 2 (potentially pivotal)	Non-Hodgkin lymphoma (NCT03888105)	Cancer	Regeneron	Zai Lab
Ociperlimab	BGB-A1217	TIGIT	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3	Non-small cell lung cancer (NCT04746924, NCT04866017)	Cancer	BeiGene
Nofazinlimab	CS1003	PD-1	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Hepatocellular carcinoma (NCT04194775)	Cancer	Cstone Pharmaceuticals	EQRx
Nipocalimab	M281	FcRn	Human mAb	Monospecific	IgG1	lambda		N297A (Fc-aglycosylated)	Phase 2/3 and Phase 3	Warm autoimmune hemolytic anemia (NCT04119050); Generalized myasthenia gravis (NCT04951622) ; Polyradiculoneuropathy (NCT05327114 pending)	Immune-mediated disorders	Janssen
Navicixizumab	OMP-305B83	DLL4, VEGF	Humanized, chimeric mAb	Bispecific	IgG2; Hetero H, cL	kappa		Hetero HH: L368E-Y407E x T357K-D399K (bispecific assembly) ; HL-pairing: cL	Phase 3 pending	Ovarian cancer/peritoneal cancer/fallopian tube cancer (NCT05043402 (not yet recruiting))	Cancer	OncXerna Theraputics, Inc.
Nadunolimab	CAN04	IL1 Receptor Accessory Protein	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 2/3 pending	Pancreatic cancer (NCT04229004)	Cancer	Cantargia AB	Pancreatic Cancer Action Network
Monalizumab	NN8765, IPH-2201, NNC141-0100	NKG2A	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Squamous Cell Carcinoma of the Head and Neck (NCT04590963)	Cancer	Novo Nordisk	AstraZeneca; Innate Pharma
Marstacimab	PF-06741086	Tissue factor pathway inhibitor	Human mAb	Monospecific	IgG1	lambda		L234A, L235A, G237A (impair Fc effector funcctions)	Phase 3	Severe hemophilia A or B (NCT03938792)	Cardiovascular / hemostasis	Pfizer
Magrolimab	ONO-7913, Hu5F9-G4	CD47	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Myelodisplastic syndromes (NCT04313881); Acute myeloid leukemia (NCT04778397, NCT05079230 (not yet recruiting))	Cancer	Gilead Sciences	Ono Pharmaceutical Co
Litifilimab	BIIB059	Blood dendritic cell antigen 2 (CD303; CLEC4C)	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3	Systemic lupus erythematosus (NCT04961567, NCT04895241)	Immune-mediated disorders	Biogen
Linvoseltamab	REGN5458	BCMA, CD3	Human mAb	Bispecific	IgG4; Hetero H, cL			Hetero HH: WT x H435R-Y436F (limits binding to Protein A, purification); HL-pairing: cL; both chains: E233P, F234V, L235A, G236del (Fc-silencing)	Phase 2 (potentially pivotal)	Multiple myeloma (NCT03761108)	Cancer	Regeneron
Ligelizumab	QGE031	IgE	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3	Chronic spontaneous urticaria (NCT03580356, NCT03580369, NCT03907878, NCT04210843); Chronic inducible urticaria (NCT05024058); Peanut allergy (NCT04984876)	Immune-mediated disorders	Tanox	Novartis
Lenzilumab		GM-CSF	Human mAb	Monospecific	IgG1	kappa		None found	Phase 3	COVID-19 pneumonia (NCT04351152, NCT04583969)	Respiratory	Humanigen
Lebrikizumab	RG3637, TNX-650, PRO301444, MILR1444A	IL-13	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Atopic dermatitis (NCT04250337, NCT04760314, NCT04146363, NCT04178967, NCT04626297, NCT04392154, NCT04250350)	Immune-mediated disorders	Genentech	Eli Lilly and Company, Almirall
Latozinemab	AL001	Sortilin	Human mAb	Monospecific	IgG1	kappa		L234A, L235A, P331S (remove Fc effector functions)	Phase 3	Frontotemporal dementia (NCT04374136)	Neurological disorders	Alector	GlaxoSmithKline
Izalontamab	SI-B001	EGFR, HER3	IgG-(scFv)2	Bispecific				None found	Phase 2/3	Non-small cell lung cancer (NCT05020457, NCT05020769)	Cancer	Biokin	Sichuan Baili Pharmaceutical Co. Ltd, SystImmune Inc.
Ivuxolimab	PF-04518600	OX40	Human mAb	Monospecific	IgG2	kappa		None found	Phase 3	Advanced malignancies (NCT05059522)	Cancer	Pfizer Inc.
Ivonescimab	AK112	PD-1, VEGF	mAb	Bispecific	IgG1-(scFv2)	kappa		L234A L235A (reduced effector function)	Phase 3	Non-small cell lung cancer (NCT05184712)	Cancer	Akesobio Australia Pty Ltd
Itepekimab	REGN3500, SAR440340	IL-33	Human mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Chronic obstructive pulmonary disease (NCT04751487, NCT04701983)	Respiratory	Regeneron	Sanofi
Iparomlimab (anti-PD-1), Tuvonralimab (anti-CTLA-4)		PD-1, CTLA-4	mAbs	Two monospecific antibodies	IgG4, IgG1	kappa		S228P IgG4 hinge stabilization; K147D F170C V173C C220G R255K D399R K409E IgG1 mutations	Phase 3 pending	Cervical cancer (NCT05446883)	Cancer	Qilu Pharmaceutical Co., Ltd.
Iodine (131I) apamistamab	I-131-BC8, Iomab-B	CD45	Murine mAb	Monospecific	IgG1	kappa	I-131	None found	Phase 3	Acute myeloid leukemia (NCT02665065)	Cancer	Actinium Pharmaceuticals
Inclacumab	RO4905417, RG1512	P-selectin (CD62)	Human mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization); L235E (impair Fc effector function)	Phase 3	Vaso-occlusive crisis in sickle cell disease patients (NCT04927247, NCT04935879)	Cardiovascular / hemostasis	Hoffmann-La Roche; Genmab	Global Blood Therapeutics
Imsidolimab	ANB019	IL-36R	Humanized mAb	Monospecific	IgG4	kappa		S228P. Hinge stabilization	Phase 3	Generalized pustular psoriasis (GEMINI-1)	Immune-mediated disorders	AnaptysBio, Inc.
Ianalumab	VAY736	BLyS/BAFF/TACI/BCMA receptor	Human mAb	Monospecific	IgG1	kappa		Afucosylated (improve FcγRIIIa binding/improve ADCC)	Phase 2/3 and Phase 3	Autoimmune hepatitis (NCT03217422); Lupus nephritis (NCT05126277 not yet recruiting)	Immune-mediated disorders	MorphoSys	Novartis
Glenzocimab	ACT017	Glycoprotein VI on platelets	Humanized Fab	Monospecific	IgG1	kappa		None found	Phase 2/3	Acute ischemic stroke (NCT05070260)	Cardiovascular disease	Acticor Biotech
Garetosmab	REGN2477	Activin A	Human mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 2 (pivotal); Phase 3 pending	Fibrodysplasia ossificans progressiva (NCT03188666; NCT05394116)	Musculoskeletal disorders	Regeneron
Garadacimab	CSL312	Factor XIIa	Human mAb	Monospecific	IgG4	lambda		S228P (hinge-stabilization)	Phase 3	Prevention of hereditary angioedema attacks (NCT04656418, NCT04739059)	Cardiovascular / hemostasis	CSL Behring
Gantenerumab	RO4909832, RG1450	Amyloid beta	Human mAb	Monospecific	IgG1	kappa		None found	Phase 3	Early Alzheimer's disease (NCT01760005, NCT03444870, NCT03443973); Alzheimer's disease (NCT04339413, NCT04374253)	Neurological disorders	Hoffmann-La Roche	MorphoSys
Futuximab+modotuximab	SYM004	EGFR	Chimeric mAbs	Mixture of 2 monospecific mAbs	IgG1	kappa		None found	Phase 3	Colorectal cancer (NCT05223673)	Cancer	Institut de Recherches Internationales Servier
Flotetuzumab	MGD006, S80880	CD123, CD3	Humanized DART®; Tandem domain-exchanged Fv; bivalent scFv-scFv (VH-VL-VH'-VL')	Bispecific				None found	Phase 2 (pivotal)	Acute myeloid leukemia (NCT04582864)	Cancer	MacroGenics
Finotonlimab	SCT-I10A, SCTI-10A	PD-1	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 2/3 and Phase 3	Hepatocellular carcinoma (NCT04560894); Non-small-cell lung cancer (NCT04171284); Head and neck squamous cell carcinoma (NCT04146402)	Cancer	Sinocelltech Ltd
Fianlimab	REGN3767	LAG-3	Human mAb	Monospecific	IgG4	kappa		S228P; E233P F234V L235A G236del. Hinge stabilization and reduced effector function	Phase 3	Melanoma (NCT05352672)	Cancer	Regeneron Pharmaceuticals	Sanofi
Felzartamab	TJ202, MOR202, MOR03087	CD38	Human mAb	Monospecific	IgG1	lambda		None found	Phase 3	Multiple myeloma (NCT03952091)	Cancer	MorphoSys AG	I-Mab Biopharma
Favezelimab	MK-4280	LAG-3	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Colorectal cancer (NCT05064059)	Cancer	Merck Sharp & Dohme Corp.
Fasinumab	REGN475, SAR164877, MT-5547	Nerve growth factor	Human mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Pain due to osteoarthritis of the knee or hip (NCT03161093, NCT02683239, NCT03304379, NCT02447276, NCT03245008); Low back pain (NCT02620020)	Neurological disorders	Regeneron	Teva, Mitsubishi Tanabe Pharma Corporation
Erfonrilimab	KN046	PD-L1, CTLA4	Humanized, chimeric mAb	Bispecific	IgG1; Hetero H; VH-VH-h-CH2-CH3 dimer	n/a		Hetero HH, HL-pairing: cL: S354C-T366W-K409A x Y349C-T366S-L368A-F405K-Y407V (bispecific assembly)	Phase 3	Non-small-cell lung cancer (NCT04474119, NCT05001724 (not yet recruting))	Cancer	Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Epcoritamab	GEN3013, DuoBody-CD-3x-CD20	CD20, CD3	Humanized mAb	Bispecific	IgG1; Hetero H	lambda/kappa		Hetero HH, HL exchanged: L234F x K409R (bispecific assembly) both chains L234F, L235E, D265A (Fc silencing)	Phase 3	Diffuse large B-cell lymphoma (NCT04628494)	Cancer	Genmab	AbbVie
Emactuzumab	RO5509554, RG7155	CD115 (aka CSF1 receptor)	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3	Tenosynovial giant cell tumor (NCT05417789)	Cancer	Hoffmann-La Roche	SynOx Therapeutics
Elranatamab	PF-06863135	BCMA, CD3	Humanized mAb	Bispecific	IgG2a			Strop Fab-arm exchange method ((WO2016/166629) CD3 antibody: IgG1RRR: 221R, 228R, K409R or IgG2deltaA-RRRR: 223R, 225R, 228R, K409R; Target antibody: IgG1EEE: 221E, 228E, L368E or IgG2deltaA-EEEE: 223E, 225E, 228E, L368E, Exchange with 1-2 mM GSH).	Phase 3	Multiple myeloma (NCT05020236)	Cancer	Pfizer
Ebronucimab	AK102	PCSK9	Human mAb	Monospecific	IgG1	lambda2		None found	Phase 3	Primary hypercholesterolemia and mixed hyperlipidemia (NCT05255094, NCT05260411)	Cardiovascular/hemostasis	Akesobio Australia Pty Ltd	Dawnrays Pharmaceutical (Holdings) Limited
Ebdarokimab	AK101	IL-12/23p40	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3	Plaque psoriasis (NCT05120297)	Immune-mediated disorders	Akesobio Australia Pty Ltd
Domvanalimab	AB154	TIGIT	Humanized mAb	Monospecific	IgG1	kappa		L234A, L235A (impair Fc effector functions)	Phase 3	Non-small cell lung cancer (NCT04736173)	Cancer	Arcus Biosciences	Gilead Sciences
Divozilimab	BCD-132	CD20	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3	Multiple sclerosis (NCT05385744)	Immune-mediated disorders	Biocad
Depemokimab	GSK3511294	IL-5	Humanized mAb	Monospecific	IgG1	kappa		M252Y, S254T, T256E (half-life extension)	Phase 3	Severe uncontrolled asthma with an eosinophilic phenotype (NCT04719832, NCT04718103, NCT04718389)	Immune-mediated disorders	GlaxoSmithKline
Datopotamab deruxtecan	DS-1062	TROP-2	Humanized mAb	Monospecific	IgG1	kappa	Conjugated to deruxtecan DX-8951 (Topoisomerase I inhibitor)	None found	Phase 3	Non-small cell lung cancer without actionable genomic alterations (NCT04656652); Breast cancer (NCT05104866)	Cancer	Daiichi-Sankyo
Dapirolizumab pegol	CDP-7657	CD40L	Humanized Fab	Monospecific	IgG1	kappa	PEGylated	None found	Phase 3	Systemic lupus erythematosus (NCT04976322, NCT04294667)	Immune-mediated disorders	UCB	Biogen
Dafsolimab setaritox + grisnilimab setaritox	T-Guard; SPV-T3a + WT1	CD3 + CD7	Mixture of two mAb murine	Two monospecific mAbs	IgG2b, IgG2a	kappa; lambda	Conjugated to ricin A	None found	Phase 3	Steroid-refractory acute graft vs. host disease (NCT04934670)	Immune-mediated disorders	Xenikos
Crovalimab	SKY59, RG6107, RO7112689	Complement C5	Humanized mAb	Monospecific	IgG1	kappa		L235R, G236R, S239K, A327G, A330S, P331S (impair Fc binding/effector functions), M428L, N434A, Q438R, S440E (increase FcnR binding without increasing RF binding)	Phase 3	Atypical hemolytic uremic syndrome (NCT04861259, NCT04958265); Paroxysmal nocturnal hemoglobinuria (NCT04434092, NCT04432584, NCT04654468)	Cardiovascular / hemostasis	Chugai	Hoffmann-La Roche
Crexavibart and ogalvibart	C144-LS and C-135-LS	SARS-CoV-2	Mixture of 2 mAbs	Two monospecific antibodies	IgG1			M428L/N434S (extends half-life)	Phase 2/3	COVID-19/SARS-CoV-2 infection (NCT04518410)	Infectious disease	Bristol-Myers Squibb	Rockefeller University
Cosibelimab	CK-301	PD-L1	Human mAb	Monospecific	IgG1	lambda		None found	Phase 1 (registrational) and Phase 3	Squamous cell carcinoma (NCT03212404) ; Non-small cell lung cancer (NCT04786964)	Cancer	Checkpoint Therapeutics, Inc.
Coprelotamab	GB221	HER2	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3	HER2+ Breast cancer (NCT04164615)	Cancer	Genor Biopharma Co., Ltd.
Concizumab	NNC172-2021, NN7415, mAb2021	Tissue factor pathway inhibitor	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 3	Hemophilia A or B with inhibitors (NCT04083781); Hemophilia A or B without inhibitors (NCT04082429)	Cardiovascular / hemostasis	Novo Nordisk
Cobolimab	GSK4069889, TSR-022	TIM-3	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 2/3	Non-small cell lung cancer (NCT04655976)	Cancer	GlaxoSmithKline
Clesrovimab	MK-1654	RSV fusion protein	Human mAb	Monospecific	IgG1	kappa		M252Y, S254T, T256E (half life extension)	Phase 2/3 and Phase 3	Reduction in incidence of respiratory syncytial virus infection (NCT04767373, NCT04938830)	Infectious disease	Merck Sharp & Dohme Corp.
Clazakizumab	ALD518; BMS-945429	IL-6	Humanized mAb	Monospecific	IgG1	kappa		N297A (Fc-aglycosylated)	Phase 3	Antibody-mediated rejection in kidney transplant recipients (NCT03744910)	Immune-mediated disorders	H. Lundbeck	Vitaeris Bio
Cetrelimab	JNJ-63723283	PD-1	Human mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization)	Phase 2/3 and Phase 3	Multiple myeloma (NCT03357952); Urinary bladder neoplasms (NCT04658862)	Cancer	Janssen Research & Development, LLC	XOMA Corporation
Cendakimab	CC-93538, RPC4046; ABT-308, 13C5.5	IL-13	Humanized mAb	Monospecific	IgG1	kappa		L234A, L235A (impair Fc effector functions)	Phase 3	Eosinophilic esophagitis (NCT04753697, NCT04991935)	Immune-mediated disorders	AbbVie	Bristol-Myers Squibb
Camidanlumab tesirine	ADCT-301	CD25	Human mAb	Monospecific	IgG1	kappa	Conjugated to pyrrolobenzodiazepine dimer SG3249	None found	Phase 2 (pivotal)	Hodgkin lymphoma (NCT04052997)	Cancer	ADC Therapeutics Sarl	AbbVie
Brazikumab	AMG139, MEDI2070	IL-23	Human mAb	Monospecific	IgG2	lambda		None found	Phase 2/3 and Phase 3	Crohn's disease (NCT03759288, NCT03961815)	Immune-mediated disorders	Amgen	AstraZeneca; AbbVie/Allergan
Birtamimab	NEOD001	Amyloid	Humanized mAb	Monospecific	IgG1	kappa		None found	Phase 3	Light chain (AL) amyloidosis (NCT04973137)	Immune-mediated disorders	Onclave Therapeutics Limited, subsidiary of Prothena
Bintrafusp alfa	M7824, MSB0011359C	PD-L1, TGFβ	Human mAb	Bispecific	IgG1	lambda	IgG1 fused with TGFbeta binding domain	None found	Phase 2/3 and Phase 3	Biliary tract cancer (NCT04066491); Non-small cell lung cancer (NCT03631706); Follow-up study to collect long-term data on participants from multiple Bintrafusp Alfa clinical studies (NCT05061823 (not yet recruiting))	Cancer	EMD Serono/Merck KGaA
Bentracimab	PB2452 (formerly MEDI2452)	Ticagrelor	Human Fab	Monospecific	Fab (IgG1 CH1)	lambda		None found	Phase 3	Reversal of the antiplatelet effects of ticagrelor in patients with uncontrolled major or life-threatening bleeding or who require urgent surgery or invasive procedure (NCT04286438)	Cardiovascular / hemostasis	AstraZeneca	PhaseBio Pharmaceuticals, Inc., Alfasigma
Bemarituzumab	FPA144	FGFR2b	Humanized mAb	Monospecific	IgG1	kappa		Afucosylated	Phase 3	Gastric cancer/gastroesophageal junction adenocarcinoma (NCT05052801)	Cancer	Amgen	Zai Lab
Batoclimab	IMVT-1401, RVT-1401, HL161BKN, HBM9161(HL161BKN), HL161	FcRn	Human mAb	Monospecific	IgG1	lambda		L234A, L235A (impair Fc effector functions)	Phase 3	Primary immune thrombocytopenic purpura (NCT04428255); Thyroid opthalmopathy (NCT05015127); Myasthenia gravis (NCT05039190)	Immune-mediated disorders	Hanall Biopharma, a subsidiary of Daewoong Pharmaceutical Co., Ltd	Harbour BioMed, Roivant Sciences / Immunovant Inc.
Apitegromab	SRK-015	Myostatin	Human mAb	Monospecific	IgG4	lambda		S228P (hinge-stabilization)	Phase 3	Spinal muscular atrophy (NCT05156320)	Muscular diseases	Scholar Rock
Anselamimab	CAEL-101, Ch mAb 11-1F4	Amyloid fibril	Chimeric mAb	Monospecific	IgG1	kappa		None found	Phase 3	Light chain (AL) amyloidosis (NCT04512235, NCT04504825)	Immune-mediated disorders	Caelum Biosciences	AstraZeneca
Anbenitamab	KN026	HER2, HER2 (biparatopic)	Humanized mAb	Bispecific	IgG1; Hetero H	kappa (common light chain)		Hetero HH, HL-pairing: cL: S354C-T366W-K409A x Y349C-T366S-L368A-F405K-Y407V (bispecific assembly)	Phase 2 (pivotal); Phase 2/3 pending	HER2+ Solid tumors (NCT04521179); HER2+ Breast cancer (NCT04165993); Gastric/Gastroesophageal junction cancer (NCT03925974, KN026-CSP-001)	Cancer	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Sanofi
Adintrevimab	ADG20	SARS-CoV-2	Human mAb	Monospecific	IgG1	lambda2		M428L/N434A (extend half-life)	Phase 2/3	COVID-19/SARS-CoV-2 infection (NCT04859517, NCT04805671)	Infectious disease	Adagio
Adebrelimab	SHR-1316, HTI-1088	PD-L1	Humanized mAb	Monospecific	IgG4	kappa		S228P (hinge-stabilization), F234A, L235A (abrogate effector function)	Phase 3	Non-small cell lung cancer (NCT04316364); Small cell lung cancer (NCT04691063, NCT03711305 (not yet recruiting))	Cancer	Jiangsu Hengrui Medicine Co.	Atridia Pty Ltd.
Abelacimab	MAA868	Factor XI	Human mAb	Monospecific	IgG1	lambda		D265A P329A. Reduced effector functions	Phase 3	Venous thromboembolism (NCT05171075, NCT05171049)	Cardiovascular/hemostasis	Novartis	Anthos Therapeutics, MorphoSys
177Lu-DOTA-rosopatamab	TLX591, ATL-101, Lu-177-huJ591	PSMA	Humanized mAb	Monospecific	IgG1	kappa	Conjugated to Lu-177	None found	Phase 3 pending	Prostate cancer (NCT04876651 (not yet recruiting))	Cancer	Telix Pharmaceuticals
	APX003, BD0801, TK001, sevacizumab	VEGF	Humanized mAb	Monospecific					Phase 3	Ovarian cancer (NCT04908787)	Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	Apexigen
	AFM13	CD30, CD16A	Human mAb; TandAb (tetravalent bispecific molecule comprising antibody variable domains with two binding sites for each antigen)	Bispecific; Tetravalent	-	-			Phase 2 (pivotal)	Peripheral T-cell lymphoma or transformed mycosis fungoides (NCT04101331)	Cancer	Affimed
	ANX005	Complement C1q	Humanized mAb	Monospecific	IgG4				Phase 2/3	Guillain-Barré syndrome (NCT04701164)	Cardiovascular / hemostasis	Annexon Biosciences
	ARX788	HER2	Humanized mAb	Monospecific	IgG1		Amberstatin 269 (Auroxime)		Phase 2 (pivotal), Phase 2/3, Phase 3	Breast cancer (NCT04829604, ACE-Breast-02 (China)); Gastric cancer (ACE-Gastric-02 (China))	Cancer	Ambrx	NovoCodex Biopharmaceuticals Co. Ltd, Zhejiang Medicine Co. Ltd
	CBT-502, TQB2450, APL-502	PD-L1	Humanized mAb	Monospecific	IgG1			Fc silenced	Phase 3	Renal cancer (NCT04523272); Non-small cell lung cancer (NCT04325763, NCT04964479); Squamous cell carcinoma of the head and neck (NCT03855384); Biliary cancer (NCT04809142)	Cancer	CBT Pharmaceuticals, Inc	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
	IBI310	CTLA-4	Humanized mAb	Monospecific	IgG1				Phase 3	Melanoma (NCT04277663); Hepatocellular carcinoma (NCT04720716)	Cancer	Innovent Biologics, Inc
	INBRX-109	DR5	Humanized mAb; sdAb (heavy chain only antibodies) fused to Fc	Monospecific; Tetravalent	IgG1			Fc silenced	Phase 2 (potentially pivotal)	Chondrosarcoma (NCT04950075)	Cancer	Inhibrx, Inc.
	JY-025	VEGFR2	Human mAb	Monospecific					Phase 2/3 pending	Non-small cell lung cancer (NCT04874844 (not yet recruiting))	Cancer	Beijing Dongfang Biotech Co., Ltd.
	MIL62	CD20	Humanized mAb	Monospecific	IgG1	kappa		Afucosylated	Phase 3	Follicular lymphoma and marginal zone lymphoma (NCT04834024)	Cancer	Beijing Mabworks Biotech Co., Ltd.
	NIS793, XOMA-089	TGF beta 1 and 2	Human mAb	Monospecific	IgG2				Phase 3	Pancreatic ductal adenocarcinoma (NCT04935359)	Cancer	XOMA Corporation	Novartis
	NNC0365-3769, Mim8	FIXa, FX	Human mAb	Bispecific	IgG4				Phase 3	Hemophilia A with or without inhibitors (NCT05053139)	Cardiovascular / hemostasis	Novo Nordisk A/S
	QL1604	PD-1	mAb	Monospecific					Phase 2/3	Cervical cancer (NCT04864782)	Cancer	Qilu Pharmaceutical Co., Ltd.
	REGN1908-1909	Fel d 1	Mixture of 2 human mAbs	Two monospecific mAbs	IgG4			S228P (hinge stabilizing)	Phase 3	Cat allergy (NCT04981717)	Immune-mediated disorders	Regeneron
	REGN5713-5714-5715	Bet v1	Mixture of 3 human mAbs	Three monospecific antibodies against three different epitopes	IgG4	kappa		S228P (hinge stabilizing)	Phase 3	Seasonal allergic rhinitis (NCT04709575)	Immune-mediated disorders	Regeneron
	RO7204239, GYM329, RG6237	Myostatin	Humanized mAb	Monospecific	IgG1			Specific mutations not found; engineered for selective and enhanced binding to the human FcγRIIb and for stronger affinity to FcRn in acidic pH conditions	Phase 2/3	Spinal muscular atrophy (NCT05115110)	Musculoskeletal disorders	Chugai	Roche
	MW33, 9MW3311, ABP-300	SARS-CoV-2	Human mAb	Monospecific	IgG1	kappa		L234A/L235A (impair Fc effector functions)	Phase 2/3	COVID-19/SARS-CoV-2 infection	Infectious disease	Mabwell (Shanghai) Bioscience Co., Ltd.	Abpro Corporation
	MAD0004J08	SARS-CoV-2	Human mAb	Monospecific	IgG1			M428L /N434S (extends half-life) L234A/L235A/P329G (impair Fc effector functions)	Phase 2/3	COVID-19/SARS-CoV-2 infection (NCT04952805)	Infectious disease	Toscana Life Sciences Sviluppo s.r.l.
	ADM03820 (COV2-2130-YTE-LALA + COV2-2381-YTE124 LALA)	SARS-CoV-2	Mixture of 2 human mAbs	Two monospecific antibodies	IgG1			M252Y/S254T/T256E (extends half-life); L234A/L235A (reduces Fc effector functions)	Phase 2/3 pending	COVID-19/SARS-CoV-2 infection (NCT05142527)	Infectious disease	Ology Bioservices / Evotec
	LMN-201	Campylobacter jejuni and enterotoxigenic E. coli exotoxin TcdB	mAb	Three monospecific nanobodies	VHH homodimers				Phase 2/3 pending	Clostridioides difficile infection (NCT05330182)	Infectious disease	Lumen Bioscience, Inc.
	TY027	SARS-CoV-2	Human mAb	Monospecific	IgG				Phase 3	COVID-19/SARS-CoV-2 infection (NCT04649515)	Infectious disease	Tychan
	HP6H8, meplazumab	CD147	Humanized mAb	Monospecific	IgG2				Phase 2/3	COVID-19	Infectious disease	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
	E2814	Tau	Humanized mAb	Monospecific	IgG1				Phase 2/3	Dominantly inherited Alzheimer's Disease (NCT05269394)	Neurological disorders	Eisai Co., Ltd.
	CM310	IL-4Rα	Humanized mAb	Monospecific					Phase 3 pending	Chronic Rhinosinusitis with nasal polyposis (NCT05436275 not yet recruiting) Atopic dermatitis (NCT05265923 not yet recruiting)	Immune-mediated disorders	Keymed Biosciences Co. Ltd
	CT-P63 and CT-P61	SARS-CoV-2 spike protein	mAb	Mixture of 2 monospecific mAbs					Phase 3 pending	COVID-19 (NCT05224856 pending)	Infectious disease	Celltrion
	SHR-A1811	HER2	mAb	Monospecific			Undisclosed		Phase 3 pending	Breast cancer (NCT05424835 not yet recruiting)	Cancer	Jiangsu HengRui Medicine Co., Ltd.
	SKB264	Trop-2	mAb	Monospecific			Belotecan-derived payload		Phase 3 pending	Triple-neg. breast cancer (NCT05347134)	Cancer	Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.